GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Beneish M-Score

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Beneish M-Score

: -1.82 (As of Today)
View and export this data going back to 2017. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.82 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Deciphera Pharmaceuticals's Beneish M-Score or its related term are showing as below:

DCPH' s Beneish M-Score Range Over the Past 10 Years
Min: -2.72   Med: -1.29   Max: 0.64
Current: -1.82

During the past 9 years, the highest Beneish M-Score of Deciphera Pharmaceuticals was 0.64. The lowest was -2.72. And the median was -1.29.


Deciphera Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Deciphera Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.64 -0.75 -2.72 -1.82

Deciphera Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.72 -2.49 -1.17 -1.53 -1.82

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Beneish M-Score falls into.



Deciphera Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Deciphera Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1689+0.528 * 0.9564+0.404 * 2.9567+0.892 * 1.2187+0.115 * 1.2023
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9318+4.679 * -0.101876-0.327 * 1.0467
=-1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $32.0 Mil.
Revenue was 48.294 + 43.313 + 38.304 + 33.445 = $163.4 Mil.
Gross Profit was 46.509 + 42.027 + 38.131 + 32.957 = $159.6 Mil.
Total Current Assets was $381.1 Mil.
Total Assets was $473.6 Mil.
Property, Plant and Equipment(Net PPE) was $37.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.1 Mil.
Selling, General, & Admin. Expense(SGA) was $136.5 Mil.
Total Current Liabilities was $100.3 Mil.
Long-Term Debt & Capital Lease Obligation was $22.4 Mil.
Net Income was -47.19 + -49.581 + -48.562 + -49.609 = $-194.9 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was -28.809 + -29.807 + -38.626 + -49.455 = $-146.7 Mil.
Total Receivables was $22.4 Mil.
Revenue was 36.345 + 35.974 + 32.494 + 29.223 = $134.0 Mil.
Gross Profit was 33.1 + 32.63 + 30.695 + 28.841 = $125.3 Mil.
Total Current Assets was $393.0 Mil.
Total Assets was $454.0 Mil.
Property, Plant and Equipment(Net PPE) was $43.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.9 Mil.
Selling, General, & Admin. Expense(SGA) was $120.2 Mil.
Total Current Liabilities was $86.5 Mil.
Long-Term Debt & Capital Lease Obligation was $25.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(31.952 / 163.356) / (22.429 / 134.036)
=0.195597 / 0.167336
=1.1689

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(125.266 / 134.036) / (159.624 / 163.356)
=0.93457 / 0.977154
=0.9564

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (381.096 + 37.494) / 473.566) / (1 - (392.958 + 43.254) / 454.039)
=0.116089 / 0.039263
=2.9567

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=163.356 / 134.036
=1.2187

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.946 / (2.946 + 43.254)) / (2.1 / (2.1 + 37.494))
=0.063766 / 0.053038
=1.2023

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(136.459 / 163.356) / (120.167 / 134.036)
=0.835347 / 0.896528
=0.9318

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((22.375 + 100.275) / 473.566) / ((25.879 + 86.469) / 454.039)
=0.258992 / 0.247441
=1.0467

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-194.942 - 0 - -146.697) / 473.566
=-0.101876

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Deciphera Pharmaceuticals has a M-score of -1.82 suggests that the company is unlikely to be a manipulator.


Deciphera Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Executives
Jama Pitman officer: SVP, Regulatory & Quality C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin officer: Chief Commercial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly officer: Chief Financial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman officer: EVP & Chief Medical Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn officer: Chief Scientific Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc 10 percent owner 1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor director, officer: See Remarks C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen director C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl officer: Chief Business Officer C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066